Technical Data
I7661-16J1
Insulin-Like Growth Factor Binding Protein 3, Recombinant Human (IGFBP3, tcag7.703, BP-53; IBP3, IGF-binding protein 3, Growth hormone-dependent binding protein)
5ug
25ug
Growth Factors, Cytokines Storage: -20CShipping: RT
Insulin Like Growth Factor Binding Protein-3 is one of the six homologous proteins that specifically bind insulin-like growth factors and modulate their mitogenic and metabolic actions. IGFBP-3 is the major IGF binding protein present in serum of humans and animals. It is also present in the alpha granules of platelets. IGFBP-3 shows a similar affinity for IGF-1 and IGF-2. IGFBP-3 inhibits follicle stimulating hormone . Markedly decreased levels of IGFBP-3 are observed in patients with growth hormone deficiencies, while markedly elevated levels are observed in patients with high levels of growth hormone (acromegaly). In murine fibroblasts the synthesis of IGFBP-3 is stimulated by mitogenic growth factors such as bombesin, vasopressin, PDGF, and EGF. In human skin fibroblasts the synthesis of IGFBP-3 is stimulated by TGF-beta.

Recombinant Human IGFBP-3 is a single, non-glycosylated polypeptide chain containing 264 amino acids and having a molecular mass of 28.8kD.

Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be Gly-Ala-Ser-Ser-Gly.

Biological Activity:
IGFBP-3 is fully biologically active when compared to standards. The ED50, calculated by by its ability to inhibit IGF-II induced proliferation of MCF-7 is less then 0.2ug/ml in the presence of 15ng/ml of Human IGF-II.

Storage and Stability:
Lyophilized powder may be stored at -20C. Reconstitute to nominal volume by adding sterile dH2O, 0.1% HSA or BSA and store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
28.8kD
Source: E. coli
Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.
Form: Supplied as a sterile filtered lyophilized powder in 20mM Tris HCl. Reconstitute in sterile ddH2O, 0.1%HSA or BSA to 0.1mg/ml, which can then be further diluted to other aqueous solutions.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Kanbur-Oksuz N, Derman O, Turk J Pediatr 2004 Oct-Dec;46(4):315-21 2. Ozon A, Alikasifoglu A, Turk J Pediatr 2004 Oct-Dec;46(4):303-8 3. Lofqvist C, Andersson E, Rosberg S, J Clin Endocrinol Metab 2004 Dec 14; 4. Silha JV, Gui Y, Leckstrom A, Endocrinology 2004 Nov 18; 5. Li Y, Xiang J, J Biol Chem 2004 Nov 17; 6. Chen C, Lewis SK, Fitzpatrick A, Cancer 2005 Jan 1;103(1):76-84.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.